GHK-Cu + CJC-1295 + Ipamorelin + TB-500 - Samson and Delilah

1 Identity

Fixed-ratio four-component article: a copper(II) coordination complex co-lyophilized with a peptide-maleimide conjugate, a non-proteinogenic pentapeptide amide and a long acetylated peptide. Not a molecule and not a single substance; a formulation. It is the most chemically heterogeneous blend in this set - a metal center, a thiol-reactive electrophile, two D-residues and an achiral non-proteinogenic residue in one vial. Two names in this title each resolve to two molecules: "CJC-1295" is used in the market both for the DAC maleimide conjugate and for the unconjugated Modified GRF (1-29), 279.30 Da apart, and "TB-500" both for the 43-mer and for the Ac-LKKTETQ heptapeptide, 4,074 Da apart. This record is the DAC-conjugate plus 43-mer specification, and neither name is accepted alone on an order or a certificate.

Contains GHK-Cu + CJC-1295 + Ipamorelin + TB-500

Sequence

Per component; each component's full identity lives on its own record and is cross-referenced rather than restated. A, GHK-Cu: ligand H-Gly-L-His-L-Lys-OH as its copper(II) complex, conventionally 1:1. B, CJC-1295 (DAC:GRF): the tetrasubstituted GHRH(1-29) analogue extended by Lys30 bearing a 3-maleimidopropionyl group on the epsilon-amine, C-terminal carboxamide, D-Ala2 the sole D-residue. C, Ipamorelin: Aib-His-D-2-Nal-D-Phe-Lys-NH2, three of five positions outside the proteinogenic set. D, full-length thymosin beta-4: Ac-SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES-OH, 43 residues, Met6 the single oxidation-labile residue. No component contains cysteine, which is the fact that governs the maleimide chemistry under Storage.

Molecular formula

Per component, never as a sum. GHK-Cu C14H22CuN6O4; CJC-1295 (DAC) C165H269N47O46; ipamorelin C38H49N9O5 as the free base; full-length thymosin beta-4 C212H350N56O78S. No combined formula is written: a mixture has no molecular formula, and a certificate printing one describes something that does not exist. Salt is stated per component - acetate or trifluoroacetate, with ipamorelin's bis-trifluoroacetate at 939.91 being 24.3 percent counterion by weight. Total nominal fill is stated instead, and only alongside the per-component fills.

Average mass

Per component: GHK-Cu 401.914 Da (copper 63.546, an isotope-weighted average and not the mass of any single molecule); CJC-1295 (DAC) 3,647.250; ipamorelin 711.868; thymosin beta-4 4,963.506. Worked example at 50 + 10 + 10 + 10 mg, 80 mg total nominal fill: 124.405, 2.742, 14.048 and 2.015 micromol - a molar ratio of 61.75 : 1.36 : 6.97 : 1.00 out of a 5 : 1 : 1 : 1 mass ratio. Copper contributes 7.905 mg, 9.88 percent of gross fill. Two comparators are excluded rather than assumed away: Modified GRF (1-29) at 3,367.954, exactly 279.30 Da lighter than the DAC conjugate, and Tb4(17-23) at 889.018.

Monoisotopic mass

Per component. GHK-Cu 401.0999 Da neutral for the 63Cu isotopologue, the 63Cu-to-65Cu envelope at 69.15 to 30.85 being part of the identity; CJC-1295 (DAC) 3,645.0155, observed only multiply charged, [M+3H]3+ 1,216.0124 and [M+4H]4+ 912.2612; ipamorelin 711.3857, [M+H]+ 712.3930 against a plus or minus 10 ppm window of plus or minus 0.0071 Da; thymosin beta-4 4,960.48632, taken from a deconvoluted charge envelope, [M+4H]4+ 1,241.12886. Identity is confirmed against all four expected neutrals in one run, with the raw envelope shown for the two large chains.

Salt / variant note

(1) the CJC fork: DAC conjugate 3,647.250 against unconjugated Modified GRF (1-29) 3,367.954, plus 279.30 Da, the cheaper article being the one most often shipped against a "CJC-1295" order. (2) the thymosin fork: 43-mer 4,963.506 against Tb4(17-23) 889.018; substituting the fragment destroys the residual-amino-acid deconvolution outright, the heptapeptide carrying no glutamate, methionine or asparagine. (3) the copper fork: 1:1 complex 401.914, mono-acetate 461.966, metal-free GHK 340.384, AHK-Cu 415.94. (4) ipamorelin salt: mono- through bis-trifluoroacetate, 24.3 percent of gross weight at the bis form. (5) ratio: no standard presentation exists.

2 Class & testing panel

Form

Fixed-ratio blend

Testing panel

P5, P3 and P1 — panel definitiontogether, as a union rather than the highest of the three, run per component and never once for the vial. P5 governs GHK-Cu - copper stoichiometry by ICP-MS, the Cu(II) d-d band, the copper isotope envelope. P3 governs CJC-1295 and ipamorelin - chiral amino acid analysis for D-Ala2 on the conjugate and for D-2-Nal3 and D-Phe4 on the pentapeptide, plus MS/MS confirmation of the achiral Aib1. P1 governs the 43-mer. Released against all three panels in full, per component. One quantitation route is composition-specific: GHK-Cu has no unique proteinogenic marker in this blend, its glycine being shared with the 43-mer and its histidine with ipamorelin, so copper by ICP-MS is the primary quantitation route for that component here and amino acid analysis cannot supply the number at all

3 Primary sources & evidence

The index reports the design and provenance of the literature, not a conclusion about effect.

Published literature exists for each component, is graded on that component's own record and is cross-referenced from here rather than restated. Full-length thymosin beta-4 carries the human data, and it is ophthalmic in design - Sosne et al., Cornea 2015, DOI 10.1097/ico.0000000000000379; Sosne et al., Int J Mol Sci 2022, DOI 10.3390/ijms24010554; and ARISE-3, NCT03937882 - while the heptapeptide fragment has no human trial identified in any registry or publication, which is one more reason the two must not share a record. Ipamorelin's originator work dates from the mid-1990s. The CJC-1295 conjugate originates with ConjuChem Biotechnologies. The GHK-Cu literature is graded D. None of it is literature about this mixture, and no published study of this fixed four-component combination was located - a statement about the search, and about the components only in the sense that the mixture has no literature of its own.

4 Storage & specification

Storage

Blue to blue-violet co-lyophilized solid in a Type I amber glass vial with a PTFE-lined closure, the headspace displaced with nitrogen and re-blanketed after any subdivision - a laboratory-chemical presentation, non-sterile, with no sterility claim. Store at -20 degrees C plus or minus 5 degrees C, tightly closed, desiccated, protected from light. The nitrogen blanket and the light protection are the specific controls for Met6 oxidation in the presence of copper, and the label states that reason. Color is an in-process identity check and is recorded at each handling step. The 43-mer is intrinsically disordered and adsorbs to glass at low concentration, so container-closure qualification includes a measured recovery check on the actual vial and stopper. Solutions are aliquoted single-use and held at -80 degrees C. The maleimide has no thiol partner in this vial, no component containing cysteine, so its route is ring-opening hydrolysis, with lysine epsilon-amine addition competitive above about pH 8; pH is a specified attribute of any solution for that reason and not an incidental one.

Shelf life

Provisional 12 months at -20 degrees C plus or minus 5 degrees C, desiccated and light-protected under inert headspace, from QA release - taken as the shortest of the four component intervals, which is CJC-1295 at 12 months against 24 for each of the other three. That interval is deliberately half the class default on the conjugate's own record, and the reason travels into the blend unchanged: maleimide ring hydrolysis proceeds in the solid state at measurable rates and is the retest-limiting attribute rather than peptide backbone degradation. Protocol: 0, 1, 3, 6, 9 and 12 months at the labeled condition with maleamic acid content and thiol-reactivity titration at every point, plus a 3-month arm at 25 degrees C and 60 percent relative humidity to set the shipping excursion tolerance. Blend-specific attributes: per-component net content, every pairwise ratio, copper stoichiometry by ICP-MS, the d-d band lambda-max, free-ligand GHK at 340.186, and Met6 sulfoxide, the last because a redox-active metal shares the vial. Extension beyond 12 months requires a completed dataset, not an argument.